Investigating how HIV-1-specific antibodies work in infants exposed to HIV-1.
Official title: Defining and modeling HIV-1-specific antibody function in HIV-1-exposed Infants passively Infused with broadly neutralizing antibodies in the IMPAACT P1112 trial.
Funded at Weill Medical Coll of Cornell Univ · NIH-11144102 · Data updated 2026-11-12
This study is looking at how well certain antibodies can help protect babies who have been exposed to HIV-1 through breastfeeding, and it’s for parents and caregivers of infants who might be at risk of HIV-1 infection.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 9, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $273,424 |
| NIH project number | 1R21HD118592-01 |
| Project ID | NIH-11144102 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants who have been exposed to HIV-1 and are receiving passive immunization with broadly neutralizing antibodies.
✕Less likely to help
Patients who are not infants or those who are not exposed to HIV-1 may not benefit from this research.
What this research studies
This research focuses on understanding the function of HIV-1-specific antibodies in infants who have been exposed to the virus and have received passive infusions of broadly neutralizing antibodies (bnAbs). The study builds on previous trials that assessed the safety and pharmacokinetics of these antibodies in infants, aiming to evaluate their effectiveness in neutralizing HIV-1 viruses found in breastmilk. By analyzing the serum from these infants, the research seeks to determine how well these antibodies can prevent HIV-1 transmission through breastfeeding. This could lead to new strategies for protecting infants from HIV-1 infection.
Why it matters
Potential benefit: If successful, this research could provide a new preventive strategy against HIV-1 transmission in infants, particularly through breastfeeding.
How similar studies have gone: Previous trials have shown promise in using broadly neutralizing antibodies for HIV prevention, indicating potential success for this approach.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Fouda Amou Ou, Genevieve Giny — Weill Medical Coll of Cornell Univ
- Study coordinator: Fouda Amou Ou, Genevieve Giny
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.